Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

IVA
Inventiva S.A.
stock NASDAQ ADR

At Close
May 8, 2025
3.52USD-2.086%(-0.08)18,855
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 5, 2025 9:13:30 AM EDT
3.49USD-2.921%(-0.11)400
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
04:08PM EST  Inventiva Receives 4M Milestone Payment From AbbVie For Cedirogant Phase IIB Initiation   Benzinga
04:00PM EST  Inventiva receives a 4 million milestone payment   GlobeNewswire Inc
Jan 20, 2022
04:00PM EST  Inventiva announces participation at several conferences in   GlobeNewswire Inc
Dec 16, 2021
04:00PM EST  Inventiva To Present At 40th Annual J.P. Morgan Healthcare Conference Jan. 13   Benzinga
04:00PM EST  Inventiva to present at the 40th Annual J.P. Morgan Healthcare   GlobeNewswire Inc
Dec 7, 2021
07:16AM EST  Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor   Benzinga
Dec 6, 2021
04:02PM EST  Inventiva Announces Results Of QT/QTc Study Conducted With Lanifibranor' Says 'Lanifibranor administered at the anticipated maximal therapeutic dose of 1200mg/day and at the supra-therapeutic dose of 2400mg/day had no impact on QT/QTc interval'   Benzinga
04:00PM EST  -- Trial conducted in 217 patients to evaluate the potential effect of lanifibranor on the QT/QTc interval in healthy subjects and to support lanifibranor New Drug Application (NDA) package in NASH   GlobeNewswire Inc
Nov 22, 2021
11:15AM EST  HC Wainwright & Co. Maintains Buy on Inventiva, Raises Price Target to $42   Benzinga
Nov 10, 2021
04:00PM EST  -- Cash and cash equivalents at 105.7m as of September 30, 2021 -- Revenues of 0.2m for the first nine months of 2021   GlobeNewswire Inc
Nov 3, 2021
04:00PM EDT  Inventiva to host a webcast with Key Opinion Leaders from the   GlobeNewswire Inc
Oct 29, 2021
09:29AM EDT  Inventiva announces participation at several conferences in   GlobeNewswire Inc
Oct 28, 2021
07:15AM EDT  Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022   Benzinga
Oct 27, 2021
04:28PM EDT  Inventiva Announces Design Of LEGEND Phase IIa Combination Trial With lanifibranor And SGLT2 Inhibitor Empagliflozin In Patients With NASH And Type 2 Diabetes   Benzinga
04:00PM EDT  Inventiva announces the design of LEGEND, a Phase IIa combination   GlobeNewswire Inc
Oct 21, 2021
12:11PM EDT  Inventiva Highlights Results Of Its NATIVE Phase 2b Trial With Lanifibranor In NASH Published In New England Journal Of Medicine   Benzinga
Oct 20, 2021
05:07PM EDT  The New England Journal of Medicine publishes the results of the   GlobeNewswire Inc
Oct 18, 2021
04:00PM EDT  Inventiva announces the presentation of five scientific abstracts   GlobeNewswire Inc
Sep 28, 2021
04:00PM EDT  Inventiva announces participation at several investor conferences   GlobeNewswire Inc
Sep 23, 2021
02:45AM EDT  -- Sale performed at a price of $14.40 per new ADS1 , without a discount to the volume weighted average price of the Company's ADS over the last trading day   GlobeNewswire Inc
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
07:01AM EDT  Fast Track Status Expanded For Inventiva's NASH Treatment   Benzinga
06:25AM EDT  HC Wainwright & Co. Maintains Buy on Inventiva, Raises Price Target to $40   Benzinga
Sep 21, 2021
04:01PM EDT  Inventiva Announces FDA Decision Saying Fast Track Designation Granted To lanifibranor In NASH Encompasses Treatment Of NASH With Compensated Cirrhosis   Benzinga
04:00PM EDT  -- The FDA decision follows the Companys Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed in August 2021   GlobeNewswire Inc
Sep 20, 2021
04:13PM EDT  Inventiva H1'21 EPS (0.60) vs (0.40) In Same Period Last Year, Sales 139K vs 161K Year Over Year, Cash, Cash Equivalents 93.6M   Benzinga
04:10PM EDT  Inventiva reports 2021 first half financial results and provides a   GlobeNewswire Inc
03:35AM EDT  Earnings Scheduled For September 20, 2021   Benzinga
Sep 16, 2021
04:01PM EDT  Inventiva Announces Major Recruitments To 'Accelerate The Development Of lanifibranor In NASH'   Benzinga
04:00PM EDT  -- Seven recruitments with solid track records and complementary profiles to reinforce Inventivas clinical expertise, medical team and corporate functions -- New recruitments further expand the Companys footprint in the United States while consolidating its presence in France   GlobeNewswire Inc
Sep 10, 2021
09:00AM EDT  Inventivas 2021 First-Half Financial Results   GlobeNewswire Inc
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Sep 8, 2021
04:02PM EDT  Inventiva Announces The Initiation Of Its Pivotal Phase III Clinical Trial Evaluating Lanifibranor In NASH   Benzinga
04:00PM EDT  Inventiva announces the initiation of its pivotal Phase III   GlobeNewswire Inc
Aug 30, 2021
04:00PM EDT  Inventiva announces participation at several investor conferences   GlobeNewswire Inc
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 2, 2021
05:00PM EDT  Inventiva Implements At-The-Market Program For $100M In Stock   Benzinga
05:00PM EDT  Inventiva announces the implementation of an At-The-Market program   GlobeNewswire Inc
Jul 28, 2021
04:01PM EDT  Inventiva Reports H1 2021 Sales 0.2M   Benzinga
04:00PM EDT  -- Cash and cash equivalents at 93.6 m as of June 30, 2021 -- Revenues of 0.2 m in H1 2021   GlobeNewswire Inc
Jun 25, 2021
07:32AM EDT  The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs   Benzinga
Jun 9, 2021
04:01PM EDT  Inventiva Announces 3 Scientific Presentations At EASL International Liver Congress 2021 And During A KOL Webcast Event   Benzinga
04:00PM EDT  Inventiva announces three scientific presentations at the EASL   GlobeNewswire Inc
May 12, 2021
04:02PM EDT  Inventiva Reports Q1 Sales 100K   Benzinga
04:00PM EDT  -- Cash and cash equivalents at 107.8m as of March 31, 2021 -- Revenues of 0.1m in Q1 2021 -- Decision by AbbVie to move into Phase IIb clinical development with cedirogant in psoriasis, following promising results in its Phase Ib clinical trial   GlobeNewswire Inc
04:22AM EDT  Earnings Scheduled For May 12, 2021   Benzinga
Apr 19, 2021
04:00PM EDT  Appointment of Martine Zimmermann as Independent Director to   GlobeNewswire Inc
Mar 8, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021   Benzinga
Mar 4, 2021
04:00PM EST  Publication of positive topline results from the NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH and decision to move into pivotal Phase III development   GlobeNewswire Inc
04:07AM EST  Earnings Scheduled For March 4, 2021   Benzinga
Feb 11, 2021
04:00PM EST  -- Cash position2 at 113.0m as of December 31, 2020 compared to 124.6 million at September 30, 2020 and 35.8 million at December 31, 2019 -- Revenues of 0.4m in 2020 compared to 7.0m in 2019 -- Successful 94.9m3 initial public offering (IPO) on the Nasdaq Global Market in the United States, extending the Companys cash runway through Q4 2022   GlobeNewswire Inc
Jan 22, 2021
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 5, 2021
10:54PM EST  The lockup period of Inventiva SA (IVA) ends on January 6.   RTTNews
04:01PM EST  Inventiva Announces Design Of Phase III Clinical Trial With lanifibranor In NASH   Benzinga
04:00PM EST  Inventiva announces design of Phase III clinical trial with   GlobeNewswire Inc
Dec 7, 2020
04:00PM EST  Inventiva announces the publication in the Journal of Hepatology   GlobeNewswire Inc
Nov 12, 2020
04:02PM EST  Inventiva Q3 Sales 300.00K   Benzinga
04:00PM EST  -- Cash and cash equivalents at 124.6m as of September 30, 2020, allowing the Company to finance its operating activities through Q4 2022 -- Revenues of 0.3m for the first nine months of 2020   GlobeNewswire Inc
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
04:01PM EST  Inventiva Receives Positive FDA Feedback To Advance Lead Drug Candidate Lanifibranor Into Pivotal Phase III NASH   Benzinga
04:00PM EST  Inventiva receives positive FDA feedback to advance its lead drug   GlobeNewswire Inc
Nov 5, 2020
04:03PM EST  Inventiva Announces The Appointment Of Dr.Michael Cooreman As Chief Medical Officer   Benzinga
Nov 2, 2020
04:01PM EST  Inventiva Announces The Publication Of A Scientific Paper on The Role Of PPARs In Treatment Of NASH In Nature Review Gastroenterology & Hepatology   Benzinga
04:00PM EST  -- PPARs are shown to be attractive therapeutic targets for the treatment of NASH, producing beneficial effects on the liver, improving features of the metabolic syndrome and mitigating the risk of related extra-hepatic diseases   GlobeNewswire Inc
02:00AM EST  Inventiva announces the additional acceptance of two late-breaking   GlobeNewswire Inc
Oct 20, 2020
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
Oct 19, 2020
04:24PM EDT  Inventiva Says FDA Has Granted Fast Track Designation To Odiparcil   RTTNews
04:02PM EDT  Inventiva Receives FDA Fast Track Designation In MPS VI For Its Clincial-Stage Asset Odiparci   Benzinga
04:00PM EDT  -- The designation is intended to accelerate the regulatory review and facilitate the overall development of odiparcil for the treatment of MPS VI patients   GlobeNewswire Inc
Oct 12, 2020
04:02PM EDT  Inventiva Receives FDA Breakthrough Therapy Designation For NASH Drug Candidate Lanifibranor   Benzinga
04:01PM EDT  Inventiva Announces That It received An FDA Breakthrough Therapy Designation For The Lead Drug Candidate Lanifibranor In NASH   Benzinga
04:00PM EDT  Inventiva receives FDA Breakthrough Therapy designation for lead   GlobeNewswire Inc
Oct 5, 2020
04:00PM EDT  Inventiva selected to present the results of its NATIVE Phase IIb   GlobeNewswire Inc
Sep 16, 2020
04:00PM EDT  H1 2020 financial results and corporate business update   GlobeNewswire Inc
Aug 5, 2020
11:45AM EDT  Roth Capital Initiates Coverage On Inventiva with Buy Rating   Benzinga
Aug 4, 2020
09:35AM EDT  Benzinga's Top Upgrades, Downgrades For August 4, 2020   Benzinga
08:27AM EDT  Stifel Initiates Coverage On Inventiva with Buy Rating, Announces Price Target of $18   Benzinga
08:25AM EDT  Guggenheim Initiates Coverage On Inventiva with Buy Rating, Announces Price Target of $26   Benzinga
Jul 15, 2020
02:40PM EDT  Inventiva announces the closing of $107.7 million initial public   GlobeNewswire Inc
Jul 14, 2020
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC